Repligen (NASDAQ:RGEN – Get Free Report) and Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.
Earnings & Valuation
This table compares Repligen and Cyclerion Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Repligen | $738.26 million | 9.03 | $48.89 million | $0.85 | 139.20 |
| Cyclerion Therapeutics | $2.07 million | 12.11 | -$3.06 million | ($0.75) | -8.51 |
Analyst Ratings
This is a summary of recent ratings and target prices for Repligen and Cyclerion Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Repligen | 1 | 2 | 10 | 1 | 2.79 |
| Cyclerion Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Repligen currently has a consensus price target of $176.92, indicating a potential upside of 49.52%. Given Repligen’s stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Cyclerion Therapeutics.
Profitability
This table compares Repligen and Cyclerion Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Repligen | 6.62% | 4.71% | 3.34% |
| Cyclerion Therapeutics | -77.02% | -24.61% | -22.43% |
Institutional and Insider Ownership
97.6% of Repligen shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 1.2% of Repligen shares are held by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Repligen has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.
Summary
Repligen beats Cyclerion Therapeutics on 12 of the 14 factors compared between the two stocks.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
